BioTime

OncoCyte has spun off as a publicly traded company from BioTime and has begun trading on the NYSE MKT under the symbol OCX.

Their combined offering will provide customers with a single solution for managing lab operations and performing sequence analysis and mutation identification.  

The partners will further develop a non-invasive, blood-based test for the early detection of lung cancer.

The researchers are working on an electronic genetic counseling platform that will be in later versions of the app.

NEW YORK (GenomeWeb) – OncoCyte and Abcodia today announced they will collaborate on the development of OncoCyte's gene expression-based diagnostic test for the early detection of breast cancer.

NEW YORK (GenomeWeb) – BioTime subsidiary OncoCyte has entered into a deal with Cornell University to collaborate on developing a lung cancer diagnostic test, the parties announced today.

NEW YORK (GenomeWeb News) – BioTime subsidiary OncoCyte today announced that it will collaborate with the Wistar Institute on the development of a gene expression-based lung cancer test.

NEW YORK (GenomeWeb News) – Cloud computing company Appistry today announced a partnership and reseller agreement to integrate LifeMap Sciences' databases into the outputs of genomics pipelines running on Appistry's Ayrris computing environment.

NEW YORK (GenomeWeb News) – LifeMap Sciences today announced an exclusive distribution deal with ProSpec-Tany TechnoGene to offer more than 1,000 recombinant proteins and antibodies.

NEW YORK (GenomeWeb News) – NanoString Technologies has obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the firm to sell the test in the European Union and other countries that recognize the CE Mark.

Pages

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.